1461-96-7 Usage
Description
CIS-CYCLOPENTANE-1,2-DICARBOXYLIC ACID, also known as (1R,2S)-rel-1,2-Cyclopentanedicarboxylic Acid, is an organic compound with a unique cyclopentane structure and two carboxylic acid functional groups. It is characterized by its potential to inhibit specific enzymes and has been identified for its possible applications in various industries.
Uses
Used in Pharmaceutical Industry:
CIS-CYCLOPENTANE-1,2-DICARBOXYLIC ACID is used as a possible inhibitor of prolidase for its potential therapeutic effects. Prolidase is an enzyme involved in the breakdown of imidodipeptides, and its inhibition may be beneficial in treating certain conditions related to abnormal peptide accumulation.
Used in Research and Development:
In the field of research and development, CIS-CYCLOPENTANE-1,2-DICARBOXYLIC ACID serves as a valuable compound for studying the structure-activity relationships of prolidase inhibitors. This knowledge can be applied to the design and synthesis of more potent and selective inhibitors, which may lead to the development of new drugs for various medical conditions.
Used in Chemical Synthesis:
CIS-CYCLOPENTANE-1,2-DICARBOXYLIC ACID can be utilized as a building block or intermediate in the synthesis of more complex organic molecules. Its unique cyclopentane framework and functional groups make it a versatile starting material for the creation of novel compounds with potential applications in various industries, such as pharmaceuticals, agrochemicals, and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 1461-96-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,4,6 and 1 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1461-96:
(6*1)+(5*4)+(4*6)+(3*1)+(2*9)+(1*6)=77
77 % 10 = 7
So 1461-96-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H10O4/c8-6(9)4-2-1-3-5(4)7(10)11/h4-5H,1-3H2,(H,8,9)(H,10,11)/t4-,5+
1461-96-7Relevant articles and documents
Bickel et al.
, p. 230,235 (1960)
-
Peters
, p. 1761,1765 (1959)
-
NOVEL HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 35, (2013/07/05)
The invention provides compounds of formula (I): wherein Rings A and A' are independently 5-membered optionally substituted aromatic heterocycles; Q is C(=O)NR1R1' or formula U is C(R4)2, O, S, S(=O)2, C(R4)2C(R4)2, CH2O, OCH2, CH2S, SCH2, CH2S(=O)2, S(=O)CH2 or C=C(Ru )2; X is CH2, CHR12, CR12R12, O, S, S(=O)2 or NRx; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor
Zhao, Gang,Souers, Andrew J.,Voorbach, Martin,Falls, H. Doug,Droz, Brian,Brodjian, Sevan,Yau, Yi Lau,Iyengar, Rajesh R.,Gao, Ju,Judd, Andrew S.,Wagaw, Seble H.,Ravn, Matthew M.,Engstrom, Kenneth M.,Lynch, John K.,Mulhern, Mathew M.,Freeman, Jennifer,Dayton, Brian D.,Wang, Xiaojun,Grihalde, Nelson,Fry, Dennis,Beno, David W. A.,Marsh, Kennan C.,Su,Diaz, Gilbert J.,Collins, Christine A.,Sham, Hing,Reilly, Regina M.,Brune, Michael E.,Kym, Philip R.
, p. 380 - 383 (2008/09/17)
A highly potent and selective DGAT-1 inhibitor was identified and used in rodent models of obesity and postprandial chylomicron excursion to validate DGAT-1 inhibition as a novel approach for the treatment of metabolic diseases. Specifically, compound 4a conferred weight loss and a reduction in liver triglycerides when dosed chronically in DIO mice and depleted serum triglycerides following a lipid challenge in a dose-dependent manner, thus, reproducing major phenotypical characteristics of DGAT-1-/- mice.
